SIGA Technologies Reports 2025 Revenue Down 32% and Net Income Down 60%; Secures New International Order
summarizeSummary
SIGA Technologies reported a significant decline in 2025 financial results, with product sales down 32% and net income down 60% year-over-year, while also announcing a new $13 million international TPOXX order for 2026.
check_boxKey Events
-
2025 Financial Performance Decline
Product sales decreased to $88.0 million in 2025 from $133.3 million in 2024, representing a 32% decline. Net income fell to $23.3 million in 2025 from $59.2 million in 2024, a 60% decrease.
-
New International Procurement Order
In January 2026, the company received a $13 million order for oral TPOXX from a customer in the Asia Pacific region, with delivery expected in 2026 as part of a recently signed multi-year contract.
-
BARDA Funding for Development
During Q2 2025, the Biomedical Advanced Research and Development Authority (BARDA) 19C contract was modified to add $27 million in funding for TPOXX pediatric development and manufacturing activities.
-
European Regulatory Update
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) is expected to confirm the positive benefit-risk balance of tecovirimat for smallpox, cowpox, and vaccinia complications, but recommend withdrawal of the mpox indication.
auto_awesomeAnalysis
The company reported a substantial year-over-year decline in its 2025 financial results, with product sales decreasing by 32% and net income by 60%. This significant drop in performance indicates challenges in its core business. However, the company also announced a new $13 million international procurement order for oral TPOXX in January 2026, providing some positive outlook for future revenues. Additionally, SIGA received $27 million in BARDA funding in Q2 2025 for TPOXX pediatric development and manufacturing, supporting long-term product pipeline and supply. Investors should monitor the impact of the new orders and the outcome of the European Medicine Agency's review, particularly the expected withdrawal of the mpox indication, which could affect future market access in Europe.
At the time of this filing, SIGA was trading at $5.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $404.6M. The 52-week trading range was $4.95 to $9.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.